Study of Senza for Pain published in Pain Medicine - Nevro Corp

Nevro Corp has announced that the 24 month results of SENZA-RCT, a prospective European clinical study using Nevro's Senza system delivering HF10 nerve stimulation therapy for patients with Chronic Pain have been published in the journal Pain Medicine. This clinical study evaluated the long-term safety and efficacy of HF10 therapy in patients with difficult-to-treat chronic, retractable low back and leg pain. At baseline, 86% of the patients included in the 24 month analysis had primary back pain and 79% had failed back surgery syndrome. After two years of HF10 therapy, the mean baseline back pain score of 8.4 out of 10.0 was reduced to 3.3. The mean baseline leg pain score of 5.4 out of 10.0 was reduced to 2.3.

The mean dosage of oral morphine equivalents per patient decreased from 84 mg/day to 27 mg/day. Disability and sleep disturbances were also significantly reduced. The safety profile of HF10 therapy was comparable to traditional SCS in terms of type and rates of complications. See: "Sustained Effectiveness of 10 kHz High-Frequency Spinal Cord Stimulation for Patients with Chronic, Low Back Pain: 24-Month Results of a Prospective Multicenter Study." Adnan Al-Kaisy et al. Pain Medicine, March 2014 (pages 347�354) 5 DEC 2013 | DOI: 10.1111/pme.12294